Search results
Added:
1 year ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical…
View more
Added:
1 year ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Added:
7 months ago
Original Research
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Shelley Zieroth, Dr Shahzeb Khan and Prof Gianluigi Savarese examine the clinical impact of hyperkalemia in heart failure and discuss strategies for its long-term management.
View more
Added:
9 months ago
This webinar series, recorded at the ESC 2025 with key opinion leaders Dr David Berg (Brigham and Women's Hospital, Boston, US) and Dr Clara Saldarriaga (Cardio VID Clinic, Medellin, CO) presenting late-breaking data, explores the evolving evidence for in-hospital initiation of guideline-directed medical therapy after an acute heart failure event. Viewers will gain insight into the persistent…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Giuseppe Rosano and Dr Stephen Greene discuss the implementation of guideline-directed medical therapy (GDMT) in heart failure and strategies to overcome clinical inertia.
View more
Added:
2 months ago
Source:
Heart Failure Academy
The European Commission has approved the non-steroidal mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia) for the treatment of adults with symptomatic chronic heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40%.¹ The approval is based on positive results from the Phase III Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients…
View more
Added:
1 year ago
THT Conference 2025 - Findings show catheter ablation of the right greater splanchnic nerve (GSN) in patients with heart failure with preserved ejection fraction (HFpEF) reduced estimated stressed blood volume in patients whether the ablation caused clinical benefits or not. This outcome indicates a confirmation of technical success that correlates with prior single-arm study findings.Dr Marat…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
An exploratory analysis of the VICTOR trial suggests that in compensated patients with heart failure and reduced ejection fraction (HFrEF), vericiguat may reduce the overall burden of worsening heart failure (HF) when outpatient events are included alongside hospitalisations.¹Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate pathway,…
View more
Added:
2 years ago
HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo,…
View more